CoChat
Sign Up
Cited by 78Treatment of Major DepressionSleep and Wakefulness ResearchSleep and related disorders

The DOI matches its Crossref record.

Fluvoxamine versus desipramine: Comparative polysomnographic effects

Kupfer, David J., Perel, James M., Pollock, Bruce G., Nathan, R.Swami, Grochocinski, Victoria J., Wilson, M.Jean, McEachran, Ann B.·1991·Biological Psychiatry
DOI 10.1016/0006-3223(91)90208-4
Open this paper in CoChat — free account

Abstract

Electroencephalogram sleep measures over a 4-week period were obtained on 35 inpatients with major depression (unipolar) who received either fluvoxamine or desipramine in a randomized double-blind trial. Fluvoxamine showed immediate rapid eye movement (REM) sleep suppression and an alerting effect on sleep continuity measures. In contrast, desipramine administration was associated with REM suppression and sleep continuity improvement. The "alerting" quality of fluvoxamine, similar to other serotonergic antidepressants, appears to be unrelated to a lack of clinical efficacy, but may be related to persistent REM sleep suppression. However, it is premature to comment on the serotonin specificity for REM sleep.

Overview

Integrity signals

Registry

Crossref · 10.1016/0006-3223(91)90208-4

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Desipramine (100-200mg) significantly reduced sleep latency after just one day of treatment, but this significantly increased again within a week and throughout the remainder of the 4-week study.

    “(Kupfer et al., 1991) demonstrated that desipramine (100-200mg) significantly reduced sleep latency after just one day of treatment, but this significantly increased again within a week and throughout the remainder of the 4-week study.”

    From Antidepressants and their effect on sleep (2005) · cites this paper as Kupfer et al., 1991

  • Desipramine was associated with shorter sleep latency than fluvoxamine (200mg), and presented better sleep efficiency.

    “Desipramine was associated with shorter sleep latency than fluvoxamine (200mg), and presented better sleep efficiency.”

    From Antidepressants and their effect on sleep (2005) · cites this paper as Kupfer et al., 1991

  • Greater sleep disruption was demonstrated for fluvoxamine (200mg) than desipramine (100-200mg).

    “(Volkers et al., 2002) found that fluvoxamine (mean 201mg) was associated with more fragmented sleep than imipramine (mean 220mg), while (Kupfer et al., 1991) demonstrated greater sleep disruption for fluvoxamine (200mg) than desipramine (100-200mg).”

    From Antidepressants and their effect on sleep (2005) · cites this paper as Kupfer et al., 1991

  • Other TCAs, such as desipramine or protriptyline, prolong sleep onset latency, reduce sleep efficiency, and increase WASO or awakenings/arousals after sleep onset.

    “Other TCAs, such as desipramine or protriptyline, prolong sleep onset latency, reduce sleep efficiency, and increase WASO or awakenings/arousals after sleep onset [Kupfer et al., 1991].”

    From Depression, sleep physiology, and antidepressant drugs (2001) · cites this paper as Kupfer et al., 1991

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 23

  1. Berger, 1989, The Cholinergic Rapid Eye Movement Sleep Induction Test with RS-86: State or trait marker of depression?, Arch Gen Psychiatry, 46, 421, 10.1001/archpsyc.1989.01810050035006 · DOI
  2. Claassen, 1983, Review of the animal pharmacology and pharmacokinetics of fluvoxamine, Br J Clin Pharmacol, 15, 3495, 10.1111/j.1365-2125.1983.tb02125.x · DOI
  3. Claassen, 1977, Fluvoxamine: A specific 5-hydroxytriptamine uptake inhibitor, Br J Pharmacol, 60, 505, 10.1111/j.1476-5381.1977.tb07528.x · DOI
  4. Doman, 1988, Computer analysis of EEG, EOG, and NPT activity during sleep, Int J Biomed Comput, 23, 191, 10.1016/0020-7101(88)90013-X · DOI
  5. Guy, 1984, A double-blind clinical trial of fluvoxamine and imipramine in patients with primary depression, Psychopharmacol Bull, 20, 73
  6. Hamilton, 1960, A rating scale for depression, J Neurol Neurosurg Psychiatry, 23, 56, 10.1136/jnnp.23.1.56 · DOI · Paper page
  7. Hyttel, 1982, Citalopram-pharmacological profile of a specific serotonin uptake inhibitor with antidepressant activity, Psychopharmacol Biol Psychiatry, 6, 277
  8. Itil, 1983, A double-blind placebo-controlled study of fluvoxamine and imipramine in outpatients with primary depression, Br J Clin Pharmacol, 15, 4335, 10.1111/j.1365-2125.1983.tb02134.x · DOI
  9. Jarrett, 1988, Acute changes in sleep-related hormone secretion of depressed patients following oral imipramine, Biol Psychiatry, 24, 541, 10.1016/0006-3223(88)90165-5 · DOI
  10. Kupfer, 1990, Clomipramine and EEG sleep in depression, Psychiatry Res, 30, 165, 10.1016/0165-1781(89)90158-3 · DOI
  11. Lapierre, 1987, Treatment of major affective disorder with fluvoxamine, J Clin Psychiatry, 48, 65
  12. McPartland, 1978, Rapid eye movement sleep cyclce, clock time and sleep onset, EEG Clin Neurophysiol, 45, 178, 10.1016/0013-4694(78)90002-0 · DOI
  13. Nathan, 1990, The role of neuropharmacological selectivity in antidepressant action: Fluvoxamine versus desipramine, J Clin Psychiatry
  14. Nicholson, 1989, Modulation of rapid eye movement sleep in humans by drugs that modify monoaminergic and purinergic transmission, Neuropsychopharmacology, 2, 131, 10.1016/0893-133X(89)90016-X · DOI
  15. Nicholson, 1986, 5-Hydroxytryptamine and noradrenaline uptake inhibition: Studies on sleep in man, Neuropharmacology, 25, 1079, 10.1016/0028-3908(86)90153-X · DOI
  16. Pollock, 1989, Acute antidepressant effect following pulse loading with intravenous and oral clomipramine, Arch Gen Psychiatry, 46, 29, 10.1001/archpsyc.1989.01810010031005 · DOI
  17. Raskin, 1969, Replication of factors of psychopathology in interview, word behavior and self-report ratings of hospitalized depressives, J Nerv Ment Dis, 148, 87, 10.1097/00005053-196901000-00010 · DOI
  18. Saletu, 1983, Pharmaco-EEG profiles of antidepressants. Pharmacodynamic studies with fluvoxamine, Br J Clin Pharmacol, 15, 369S, 10.1111/j.1365-2125.1983.tb02128.x · DOI
  19. Schenk, 1981, Double-blind comparisons of a selective serotonin reuptake inhibitor, zimelidine, and placebo on quantified EEG parameters and psychological variables, Acta Psychiatr Scand, 303, 10.1111/j.1600-0447.1981.tb00734.x · DOI
  20. Shipley, 1984, Differential effects of amitriptyline and of zimelidine on the sleep electroencephalogram of depressed patients, Clin Pharmacol Ther, 36, 251, 10.1038/clpt.1984.171 · DOI · Paper page
  21. Shipley, 1985, Comparison of effects of desipramine and amitryptiline on EEG sleep of depressed patients, Psychopharmacology, 85, 14, 10.1007/BF00427316 · DOI · Paper page
  22. Spitzer, 1978, Research Diagnostic Criteria: Rationale and reliability, Arch Gen Psychiatry, 36, 773, 10.1001/archpsyc.1978.01770300115013 · DOI
  23. Stewart, 1980, Efficacy of desipramine in endogeneomorphically depressed patients, J Affective Disord, 2, 165, 10.1016/0165-0327(80)90003-8 · DOI

Cited by

Sorted by citations

Metadata

Authors
Kupfer, D. J., Perel, J. M., Pollock, B. G., Nathan, R. S., Grochocinski, V. J., Wilson, M. J., & McEachran, A. B.
Affiliations
University of Pittsburgh (US)
Corresponding author
Kupfer, David J.
ORCID
Venue
Biological Psychiatry
Publisher
Elsevier BV
Published
1991-01
Volume
29
Issue
1
Pages
23-40
ISSN
0006-3223 (ISSN-L)
DOI
10.1016/0006-3223(91)90208-4
OpenAlex
W2080678349
Cited by
78
References
0
Citations by year
2026: 1 · 2022: 1 · 2021: 1 · 2019: 1 · 2017: 1 · 2016: 5 · 2015: 1 · 2012: 2
FWCI
5.48
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Biological Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • John D. and Catherine T. MacArthur Foundation
  • National Institute of Mental Health (MH-24652, MH-30915)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Life Sciences › Neuroscience › Cognitive Neuroscience › Sleep and Wakefulness Research
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Sleep and related disorders
Keywords
fluvoxamine, desipramine, major depressive disorder, REM sleep suppression, sleep continuity, serotonergic antidepressants, antidepressant side effects, alertness
MeSH terms
Adult, Antidepressive Agents, Arousal, Delta Rhythm, Depressive Disorder, Desipramine, Double-Blind Method, Electroencephalography, Female, Humans, Male, Middle Aged, Oximes, Signal Processing, Computer-Assisted, Sleep, REM, Fluvoxamine

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review